John Huggins to Disease Progression
This is a "connection" page, showing publications John Huggins has written about Disease Progression.
Connection Strength
0.156
-
Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. Respir Med. 2019 04; 150:120-125.
Score: 0.033
-
Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018 Dec 31; 27(150).
Score: 0.032
-
Lung function outcomes in the INPULSIS? trials of nintedanib in idiopathic pulmonary fibrosis. Respir Med. 2019 01; 146:42-48.
Score: 0.032
-
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019 Jan; 7(1):60-68.
Score: 0.032
-
First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of?=50?% of Predicted Value. Lung. 2016 10; 194(5):739-43.
Score: 0.027